1. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC: Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2019, 69:184-210.
2. Zheng P, Liu Y, Chen J, Xu W, Li G, Ding J: Targeted pH-responsive polyion complex micelle for controlled intracellular drug delivery. Chinese Chemical Letters 2020, 31:1178-1182.
3. Wang Y, Wang X, Zhang J, Wang L, Ou C, Shu Y, Wu Q, Ma G, Gong C: Gambogic acid-encapsulated polymeric micelles improved therapeutic effects on pancreatic cancer. Chinese Chemical Letters 2019, 30:885-888.
4. Paul S, Moye-Rowley WS: Multidrug resistance in fungi: regulation of transporter-encoding gene expression. Front Physiol 2014, 5:143.
5. Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, Lee RJ: Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 2007, 10:350-357.
6. Huo Q, Zhu J, Niu Y, Shi H, Gong Y, Li Y, Song H, Liu Y: pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer. Int J Nanomedicine 2017, 12:8631-8647.
7. Wang J, Wang F, Li F, Zhang W, Shen Y, Zhou D, Guo S: A multifunctional poly(curcumin) nanomedicine for dual-modal targeted delivery, intracellular responsive release, dual-drug treatment and imaging of multidrug resistant cancer cells. J Mater Chem B 2016, 4:2954-2962.
8. Zhou Y, Wang S, Ying X, Wang Y, Geng P, Deng A, Yu Z: Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer. Int J Nanomedicine 2017, 12:6153-6168.
9. Zhang X, He F, Xiang K, Zhang J, Xu M, Long P, Su H, Gan Z, Yu Q: CD44-Targeted Facile Enzymatic Activatable Chitosan Nanoparticles for Efficient Antitumor Therapy and Reversal of Multidrug Resistance. Biomacromolecules 2018, 19:883-895.
10. Cao Y, Wei Z, Li M, Wang H, Yin L, Chen D, Wang Y, Chen Y, Yuan Q, Pu X, et al: Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension. Curr Cancer Drug Targets 2019, 19:338-347.
11. Kou L, Sun R, Xiao S, Cui X, Sun J, Ganapathy V, Yao Q, Chen R: OCTN2-targeted nanoparticles for oral delivery of paclitaxel: differential impact of the polyethylene glycol linker size on drug delivery in vitro, in situ, and in vivo. Drug Deliv 2020, 27:170-179.
12. Li H, Li J, He X, Zhang B, Liu C, Li Q, Zhu Y, Huang W, Zhang W, Qian H, Ge L: Histology and antitumor activity study of PTX-loaded micelle, a fluorescent drug delivery system prepared by PEG-TPP. Chinese Chemical Letters 2019, 30:1083-1088.
13. Zhang B, Xue A, Zhang C, Yu J, Chen W, Sun D: Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel. Pharmazie 2016, 71:320-326.
14. Fjallskog ML, Frii L, Bergh J: Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet 1993, 342:873.
15. Rowinsky EK, Donehower RC: Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014.
16. MalingrГ© MM, Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Huinink WW, Swart M, Lieverst J, Schellens JH: Phase I and pharmacokinetic study of oral paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000, 18:2468.
17. Jang SH, Wientjes MG, Au JLS: Kinetics of P-glycoprotein-mediated efflux of paclitaxel. Journal of Pharmacology and Experimental Therapeutics 2001, 298:1236-1242.
18. Gallo JM, Li S, Guo P, Reed K, Ma J: The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 2003, 63:5114-5117.
19. Li M, Chen Y, Yin L, Wang H, Cao Y, Wei Z, Wang Y, Yuan Q, Pu X, Zong L: Formulation and Stability Evaluation of Structure-Altered Paclitaxel Nanosuspensions Stabilized by a Biocompatible Amino Acid Copolymer. Sci Adv Mater 2017, 9:1713-1723.
20. Yu M, Su D, Yang Y, Qin L, Hu C, Liu R, Zhou Y, Yang C, Yang X, Wang G, Gao H: D-T7 Peptide-Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Antiangiogenesis and Chemotherapy of Glioma. ACS Appl Mater Interfaces 2019, 11:176-186.
21. Zhang J, Du Q, Song X, Gao S, Pang X, Li Y, Zhang R, Abliz Z, He J: Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging. Theranostics 2020, 10:2621-2630.
22. Ding D, Sun B, Cui W, Chen Q, Zhang X, Zhang H, He Z, Sun J, Luo C: Integration of phospholipid-drug complex into self-nanoemulsifying drug delivery system to facilitate oral delivery of paclitaxel. Asian journal of pharmaceutical sciences 2019, 14:552-558.
23. Liu Y, Sun J, Cao W, Yang J, Lian H, Li X, Sun Y, Wang Y, Wang S, He Z: Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm 2011, 421:160-169.
24. Chang S, Wang Y, Zhang T, Pu X, Zong L, Zhu H, Zhao L, Feng B: Redox-Responsive Disulfide Bond-Bridged mPEG-PBLA Prodrug Micelles for Enhanced Paclitaxel Biosafety and Antitumor Efficacy. Front Oncol 2019, 9:823.
25. Luo C, Sun B, Wang C, Zhang X, Chen Y, Chen Q, Yu H, Zhao H, Sun M, Li Z, et al: Self-facilitated ROS-responsive nanoassembly of heterotypic dimer for synergistic chemo-photodynamic therapy. Journal of Controlled Release 2019, 302:79-89.
26. Luo C, Sun J, Liu D, Sun B, Miao L, Musetti S, Li J, Han X, Du Y, Li L, et al: Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy. Nano Lett 2016, 16:5401-5408.
27. Zong L, Li X, Wang H, Cao Y, Yin L, Li M, Wei Z, Chen D, Pu X, Han J: Formulation and characterization of biocompatible and stable I.V. itraconazole nanosuspensions stabilized by a new stabilizer polyethylene glycol-poly(beta-Benzyl-l-aspartate) (PEG-PBLA). Int J Pharm 2017, 531:108-117.
28. He M, Yu L, Yang Y, Zou B, Ma W, Yu M, Lu J, Xiong G, Yu Z, Li A: Delivery of triptolide with reduction-sensitive polymer nanoparticles for liver cancer therapy on patient-derived xenografts models. Chinese Chemical Letters 2020.
29. Zong L, Wang Y, Qiao P, Yu K, Hou X, Wang P, Zhang Z, Pang X, Pu X, Yuan Q: Reduction-sensitive poly(ethylene glycol)–polypeptide conjugate micelles for highly efficient intracellular delivery and enhanced antitumor efficacy of hydroxycamptothecin. Nanotechnology 2020, 31:165102.
30. Liu MC, Liu B, Sun XY, Lin HC, Lu JZ, Jin SF, Yan SQ, Li YY, Zhao P: Core/Shell Structured Fe(3)O(4)@TiO(2)-DNM Nanospheres as Multifunctional Anticancer Platform: Chemotherapy and Photodynamic Therapy Research. J Nanosci Nanotechnol 2018, 18:4445-4456.
31. Luo C, Sun J, Sun B, Liu D, Miao L, Goodwin TJ, Huang L, He Z: Facile Fabrication of Tumor Redox-Sensitive Nanoassemblies of Small-Molecule Oleate Prodrug as Potent Chemotherapeutic Nanomedicine. Small 2016, 12:6353-6362.
32. Pu X, Zhao L, Li J, Song R, Wang Y, Yu K, Hou X, Qiao P, Zong L, Chang S: A polymeric micelle with an endosomal pH-sensitivity for intracellular delivery and enhanced antitumor efficacy of hydroxycamptothecin. Acta Biomater 2019, 88:357-369.
33. Liu H, Wu S, Yu J, Fan D, Ren J, Zhang L, Zhao J: Reduction-sensitive micelles self-assembled from amphiphilic chondroitin sulfate A-deoxycholic acid conjugate for triggered release of doxorubicin. Mater Sci Eng C Mater Biol Appl 2017, 75:55-63.
34. Collnot EM, Baldes C, Wempe MF, Kappl R, Huttermann J, Hyatt JA, Edgar KJ, Schaefer UF, Lehr CM: Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007, 4:465-474.
35. Gao Y, Li LB, Zhai G: Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin. Colloids Surf B Biointerfaces 2008, 64:194-199.
36. Tung NT, Tran CS, Pham TM, Nguyen HA, Nguyen TL, Chi SC, Nguyen DD, Bui TB: Development of solidified self-microemulsifying drug delivery systems containing l-tetrahydropalmatine: Design of experiment approach and bioavailability comparison. Int J Pharm 2018, 537:9-21.
37. Taheri M, Bagheri M, Moazeni-Pourasil RS, Ghassempour A: Response surface methodology based on central composite design accompanied by multivariate curve resolution to model gradient hydrophilic interaction liquid chromatography: Prediction of separation for five major opium alkaloids. J Sep Sci 2017, 40:3602-3611.
38. Sun B, Luo C, Yu H, Zhang X, Chen Q, Yang W, Wang M, Kan Q, Zhang H, Wang Y, et al: Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy. Nano Lett 2018, 18:3643-3650.
39. Yu W, Shevtsov M, Chen X, Gao H: Advances in aggregatable nanoparticles for tumor-targeted drug delivery. Chinese Chemical Letters 2020, 31:1366-1374.
40. Chi Y, Yin X, Sun K, Feng S, Liu J, Chen D, Guo C, Wu Z: Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J Control Release 2017, 261:113-125.
41. Yang X, Cai X, Yu A, Xi Y, Zhai G: Redox-sensitive self-assembled nanoparticles based on alpha-tocopherol succinate-modified heparin for intracellular delivery of paclitaxel. J Colloid Interface Sci 2017, 496:311-326.
42. Yang B, Wang K, Zhang D, Ji B, Zhao D, Wang X, Zhang H, Kan Q, He Z, Sun J: Polydopamine-modified ROS-responsive prodrug nanoplatform with enhanced stability for precise treatment of breast cancer. RSC Advances 2019, 9:9260-9269.
43. Sun B, Luo C, Zhang X, Guo M, Sun M, Yu H, Chen Q, Yang W, Wang M, Zuo S, et al: Probing the impact of sulfur/selenium/carbon linkages on prodrug nanoassemblies for cancer therapy. Nat Commun 2019, 10:3211.
44. Chen ZP, Zhu JB, Chen HX, Xiao YY, Feng MS, Cai H, Chen J, Cai BC: Synthesis of a novel polymer bile salts-(polyethylene glycol)2000-bile salts and its application to the liver-selective targeting of liposomal DDB. Drug Dev Ind Pharm 2010, 36:657-665.
45. Chen ZP, Xiao L, Liu W, Liu D, Xiao YY, Chen J, Liu X, Li WD, Li W, Cai BC: Novel materials which possess the ability to target liver cells. Expert Opinion on Drug Delivery 2012, 9:649-656.
46. Putz G, Schmider W, Nitschke R, Kurz G, Blum HE: Synthesis of phospholipid-conjugated bile salts and interaction of bile salt-coated liposomes with cultured hepatocytes. J Lipid Res 2005, 46:2325-2338.
47. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM: Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
48. Li Z, Zhu J, Wang Y, Zhou M, Li D, Zheng S, Yin L, Luo C, Zhang H, Zhong L, et al: In situ apolipoprotein E-enriched corona guides dihydroartemisinin-decorating nanoparticles towards LDLr-mediated tumor-homing chemotherapy. Asian J Pharm Sci 2020, 15:482-491.
49. Wang Y, Song J, Chow SF, Chow AH, Zheng Y: Particle size tailoring of ursolic acid nanosuspensions for improved anticancer activity by controlled antisolvent precipitation. Int J Pharm 2015, 494:479-489.
50. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM: Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness. The American Journal of Pathology 2000, 156:1363-1380.